The pathogenic process underlying atherosclerosis is known to resemble a chronic inflammatory reaction in which components of the complement system are involved. Similarly, the complement system is widely known to play an important role in the clinical course and pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). RA and SLE have been associated with an acelerated atherosclerosis. Our first aim will be to evaluate the association of circulating complement proteins and activity assays with arterial plaques, intima media thickness and endothelial dysfunction of the carotid arteries in patients with SLE or AR as well as in healthy subjects. We will then attempt to evaluate whether complement system abnormalities are related to determinants of cardiovascular disease such as, among others, the inflammatory dyslipidemia and insulin resistance that these diseases exhibit. Specific complement system patterns of activation/suppression, obtained through predictive multivariable regression models, will be defined for these associations. Cross-sectional study of 286 patients with RA, 286 with SLE and 286 controls. A prospective study involving a subgroup of RA patients treated with anti-TNF will be undertaken to study the influence of these treatments on complement system molecules and to determine whether the changes in dyslipidemia and insulin resistance that these treatment exert can be explained by the modifications produced in the complement system. Our study should shed new light on the relationship between inflammation and cardiovascular disease.
Artritis reumatoide
lupus eritematoso sistémico
sistema del complemento
ateromatosis subclínica
Acción Estratégica en Salud (AES)
01/01/2021 - 31/12/2023
IVAN ALEJANDRO FERRAZ AMARO
FUNDACION CANARIA INSTITUTO DE INVESTIGACION SANITARIA DE CANARIAS
HOSPITAL UNIVERSITARIO DE CANARIAS
CANARIAS
SANTA CRUZ DE TENERIFE
135,520 €